FMFranck Morceau

Franck Morceau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Franck Morceau has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient Management

    by Jinhee Kim, Franck Morceau, Yong-Jun Kwon, Yong Jae Shin

    Minimal residual disease (MRD) refers to the persistence of low-level malignant cells or tumor-derived nucleic acids that remain after curative-intent therapy and are undetectable by conventional diagnostic methods. In oncology, MRD has emerged as a powerful biomarker with well-established prognostic value in hematologic malignancies and rapidly expanding relevance in solid tumors. Advances in sensitive detection technologies, including multiparameter flow cytometry, quantitative real-time polymerase chain reaction, next-generation sequencing, and digital polymerase chain reaction, have enabled the identification of residual disease at the molecular level, often preceding clinical or radiological relapse. Beyond its conventional role as a binary indicator of treatment response or cure, MRD is increasingly recognized as a dynamic longitudinal biomarker that supports personalized disease management. Within this evolving paradigm, patient-informed MRD strategies that incorporate tumor-specific molecular profiling and serial monitoring, particularly through circulating tumor DNA, offer the potential to guide treatment adaptation, including escalation, de-escalation, maintenance optimization, and surveillance strategies across both hematologic and solid malignancies. In this review, we summarize the biological basis of MRD, current and emerging detection methodologies, and clinical applications across cancer types, with a focus on patient-informed approaches. We also discuss key limitations, including assay standardization, biological variability in solid tumors, and the lack of clearly defined actionability thresholds. Finally, we highlight future directions for integrating MRD with multi-omics and AI-driven analytical frameworks to enable adaptive, risk-informed cancer management and advanced precision oncology.

  • Open Access

    Minimal Residual Disease in Oncology: From Cure to Longitudinal Patient Management

    by Jinhee Kim, Franck Morceau, Yong-Jun Kwon, Yong Jae Shin

    Minimal residual disease (MRD) refers to the persistence of low-level malignant cells or tumor-derived nucleic acids that remain after curative-intent therapy and are undetectable by conventional diagnostic methods. In oncology, MRD has emerged as a powerful biomarker with well-established prognostic value in hematologic malignancies and rapidly expanding relevance in solid tumors. Advances in sensitive detection technologies, including multiparameter flow cytometry, quantitative real-time polymerase chain reaction, next-generation sequencing, and digital polymerase chain reaction, have enabled the identification of residual diseases at the molecular level, often preceding clinical or radio-logical relapse. Beyond its conventional role as a binary indicator of treatment response or cure, MRD is increasingly recognized as a dynamic longitudinal biomarker that supports personalized disease management. Within this evolving paradigm, patient-informed MRD strategies that incorporate tumor-specific molecular profiling and serial monitoring, particularly through circulating tumor DNA, offer the potential to guide treatment adaptation, including escalation, de-escalation, maintenance optimization, and surveillance strategies across both hematologic and solid malignancies. In this review, we summarize the biological basis of MRD, current and emerging detection methodologies, and clinical applications across cancer types, with a focus on patient-informed approaches. We also discuss key limitations, including assay standardization, biological variability in solid tumors, and the lack of clearly defined actionability thresholds. Finally, we highlight future directions for integrating MRD with multi-omics and AI-driven analytical frame-works to enable adaptive, risk-informed cancer management and advanced precision oncology.

  • Open Access

    Pancreatic Cancer Organoids: Modeling Disease and Guiding Therapy

    by Franck Morceau, Victoria El-Khoury, Kyeong Lee, Marc Jean Berna, Yong-Jun Kwon

    Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. An unmet need exists for reliable biomarkers and in vitro models capable of predicting patient drug response to advance personalized medicine. Traditional models fail to represent the tumor’s complexity and the role of the stromal environment in chemoresistance. Patient-derived organoids (PDOs) overcome these limitations, enabling multi-omics profiling and reliable drug testing for functional precision medicine. This review provides a comprehensive overview of PDAC PDO research, emphasizing the following major areas: (i) the genetic and phenotypic fidelity of PDOs, (ii) their predictive value for drug response and chemoresistance, (iii) the integration of the extracellular matrix and tumor microenvironment (TME) components, and (iv) emerging technologies. Studies confirm that PDOs faithfully represent the primary tumor’s specific genetic features and retain intratumoral heterogeneity. PDO-based platforms have demonstrated a strong correlation between in vitro drug sensitivity and in vivo efficacy in xenograft models, validating their utility for identifying drug candidates, repurposing existing drugs, and determining effective combinations. Efforts are ongoing to integrate crucial TME components, like cancer-associated fibroblasts, using innovative co-culture platforms such as fused PDOs and InterOMaX, to better model desmoplasia and chemoresistance mechanisms. Furthermore, PDO technology is converging with microphysiological systems and artificial intelligence tools to facilitate high-throughput drug screening and dynamic, real-time monitoring of therapeutic effects. The integration of PDOs into biobanks and advanced screening platforms holds the potential to accelerate drug discovery and improve therapeutic outcomes for PDAC patients, if challenges related to protocol standardization and regulatory acceptance are addressed.


  • Open Access

    TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia

    by Aurélien Pottier, Sujung Park, Yejin Lee, Francesca Liccardo, Haeun Yang, Jeonghye Park, Anne Lorant, Michael Schnekenburger, Davide Brusa, Vladimir Li, et al.